ES2309238T3 - Composicion farmaceutica que contiene el receptor fc gamma iib soluble. - Google Patents

Composicion farmaceutica que contiene el receptor fc gamma iib soluble. Download PDF

Info

Publication number
ES2309238T3
ES2309238T3 ES02803402T ES02803402T ES2309238T3 ES 2309238 T3 ES2309238 T3 ES 2309238T3 ES 02803402 T ES02803402 T ES 02803402T ES 02803402 T ES02803402 T ES 02803402T ES 2309238 T3 ES2309238 T3 ES 2309238T3
Authority
ES
Spain
Prior art keywords
pharmaceutical composition
disease
soluble
seq
case
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES02803402T
Other languages
English (en)
Spanish (es)
Inventor
Robert Huber
Peter Sondermann
Uwe Jacob
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Max Planck Gesellschaft zur Foerderung der Wissenschaften
Original Assignee
Max Planck Gesellschaft zur Foerderung der Wissenschaften
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft zur Foerderung der Wissenschaften filed Critical Max Planck Gesellschaft zur Foerderung der Wissenschaften
Application granted granted Critical
Publication of ES2309238T3 publication Critical patent/ES2309238T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES02803402T 2001-11-22 2002-11-21 Composicion farmaceutica que contiene el receptor fc gamma iib soluble. Expired - Lifetime ES2309238T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10157290 2001-11-22
DE10157290A DE10157290A1 (de) 2001-11-22 2001-11-22 Pharmazeutische Zusammensetzung enthaltend sFcRgamma IIb oder sFcRgamma III

Publications (1)

Publication Number Publication Date
ES2309238T3 true ES2309238T3 (es) 2008-12-16

Family

ID=7706571

Family Applications (1)

Application Number Title Priority Date Filing Date
ES02803402T Expired - Lifetime ES2309238T3 (es) 2001-11-22 2002-11-21 Composicion farmaceutica que contiene el receptor fc gamma iib soluble.

Country Status (10)

Country Link
US (2) US20050002924A1 (enExample)
EP (1) EP1446139B1 (enExample)
JP (1) JP5414959B2 (enExample)
AT (1) ATE409045T1 (enExample)
AU (1) AU2002366200A1 (enExample)
CA (1) CA2506068C (enExample)
CO (1) CO5590936A2 (enExample)
DE (2) DE10157290A1 (enExample)
ES (1) ES2309238T3 (enExample)
WO (1) WO2003043648A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1709073B1 (en) 2003-11-26 2011-08-10 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. SUBSTANCE BINDING HUMAN IgG Fc RECEPTOR IIb (FcgammaRIIb)
US10669324B2 (en) 2012-10-30 2020-06-02 Suppremol Gmbh Vector encoding an Fc gamma receptor IIB protein and composition of the encoded protein
EP2914623B1 (en) 2012-10-30 2016-12-28 SuppreMol GmbH A pharmaceutical composition for use in treating or preventing either one or both of an inflammatory disease and an autoimmune disease
US10028998B2 (en) * 2012-10-30 2018-07-24 Suppremol Gmbh Method for treating an inflammatory disease and/or an autoimmune disease with a soluble FcγRIIb
AU2012244302B2 (en) * 2012-10-31 2014-08-21 Suppremol Gmbh A method for treating or preventing either one or both of an inflammatory disease and an autoimmune disease
EP2796144A1 (en) 2013-04-26 2014-10-29 SuppreMol GmbH Highly concentrated Formulations of soluble Fc receptors
EP2833139A1 (en) 2013-08-01 2015-02-04 SuppreMol GmbH In vitro method for determining the stability of compositions comprising soluble Fc gamma receptor(s)
EP2837637A1 (en) 2013-08-16 2015-02-18 SuppreMol GmbH Novel anti-FcyRIIB IgG-type antibody
JP6893223B2 (ja) * 2013-10-16 2021-06-23 ズプレモル ゲーエムベーハー 医薬品組成物およびキット
KR102138219B1 (ko) 2013-10-16 2020-07-28 수프레몰 게엠베하 자가면역 수포성 질환의 치료를 위한 가용성 Fc 감마 수용체
JP2018050616A (ja) 2016-09-23 2018-04-05 東ソー株式会社 改良型組換えＦｃγＲＩＩ

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999040117A1 (en) * 1998-02-06 1999-08-12 Ilexus Pty. Limited THREE-DIMENSIONAL STRUCTURES AND MODELS OF Fc RECEPTORS AND USES THEREOF
EP1006183A1 (en) * 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Recombinant soluble Fc receptors
EP1201681A1 (en) * 2000-10-30 2002-05-02 Millennium Pharmaceuticals, Inc. "Fail" molecules and uses thereof

Also Published As

Publication number Publication date
CO5590936A2 (es) 2005-12-30
JP5414959B2 (ja) 2014-02-12
AU2002366200A1 (en) 2003-06-10
WO2003043648A2 (de) 2003-05-30
DE10157290A1 (de) 2003-06-05
AU2002366200A8 (en) 2003-06-10
EP1446139A2 (de) 2004-08-18
US20050002924A1 (en) 2005-01-06
JP2005515981A (ja) 2005-06-02
CA2506068C (en) 2011-09-20
WO2003043648A3 (de) 2004-01-08
DE50212814D1 (de) 2008-11-06
CA2506068A1 (en) 2003-05-30
ATE409045T1 (de) 2008-10-15
US20080214459A1 (en) 2008-09-04
EP1446139B1 (de) 2008-09-24

Similar Documents

Publication Publication Date Title
ES2539778T3 (es) Proteínas de fusión humanas recombinantes de EPO-Fc con vida media prolongada y actividad eritropoyética in vivo mejorada
JP4502580B2 (ja) 敗血症の治療または予防のためのｉｌ−１８阻害剤の使用
ES2494792T3 (es) Polipéptidos de acción prolongada y métodos para producirlos y administrarlos
ES2207759T3 (es) Terapia de combinacion que utiliza una proteina de union del factor de necrosis tumoral (tnf) en el tratamiento de enfermedades inducidas por el tnf.
ES2346184T3 (es) Antagonistas de cd30 o cd30l para usar en el tratamiento de enfermedades antiinflamatorias cronicas y autoinmunes.
ES2826445T3 (es) Uso médico de CD24 soluble
ES2309238T3 (es) Composicion farmaceutica que contiene el receptor fc gamma iib soluble.
JPH05507197A (ja) 結合部位を含む可溶性ペプチド類縁体
AU2008355596B2 (en) Melanocortin receptor binding mimetibodies, compositions, methods and uses
ES2243942T3 (es) Isoforma intracelular del antagonista del receptor de la interleuquina.
ES2700149T3 (es) Proteínas de fusión de UTI
ES2239019T3 (es) Factor de activacion de citoquina altamente purificada y procedimientos de uso.
ES2535156T3 (es) Uso de quimera IL6R/IL6 en la regeneración de células nerviosas
ES2363023T3 (es) Mimeticuerpos de unión a receptor de melanocortina, composiciones, procedimientos y usos.
TW202143996A (zh) 使用可溶性ｃｄ２４治療病毒性肺炎之方法
CN119522234A (zh) 新型cd200融合蛋白
JP2021506772A (ja) 視神経脊髄炎の処置のための組換えＩｇＧ Ｆｃ多量体
ES2386335T3 (es) Receptor Fc-gamma para el tratamiento de la esclerosis múltiple mediada por los linfocitos B
ES2617084T3 (es) Uso de inhibidores de IL-18 para tratar o prevenir lesiones en el SNC
JP7649923B2 (ja) ＧＰＣ３標的化抗体インターフェロンα融合タンパク質及びその使用
JP7606173B2 (ja) Ｉ型インターフェロンの中和型Ｆｃ融合タンパク質及びその使用
US20250340607A1 (en) Antigen tolerance induction through use of flt3l variants
ES2289303T3 (es) Factor de necrosis tumoral combinado con interferon en enfermedades desmielinantes.
CA2580426A1 (en) Deglycosylated and desialidated long pentraxin ptx3
JP6488376B2 (ja) 免疫原性を低減するかまたは予防するためのヒト化コブラ毒因子を含む医薬組成物、薬剤および組み合わせ医薬